Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Greenlights Shionogi’s Stable Supply Plan for 2 Cephalosporin Antibiotics
August 2, 2023
- Mitsubishi Tanabe Drops Once-Daily Oral Edaravone Regimen for ALS
August 2, 2023
- Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
- Kaken’s Burn Eschar Remover NexoBrid Now Available in Japan
August 2, 2023
- Lonsurf-Bevacizumab Combo Approved in EU for Colorectal Cancer: Taiho
August 2, 2023
- Astellas’ Zolbetuximab Accepted for Review in China for CLDN18.2 Gastric Cancer
August 2, 2023
- AbbVie Merges Allergan in Japan after Global Acquisition
August 2, 2023
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
- Astellas to Cut 500 More Jobs in Buyout Targeting Commercial Unit
August 2, 2023
- Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
August 1, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Mitsubishi Tanabe Rolls Out Tardive Dyskinesia Drug in Thailand
August 1, 2023
- Zeria’s Swiss Unit Launches JV in US to Develop Oral mAb for Ulcerative Colitis
July 31, 2023
- Novo Seeks Label Expansion of Concizumab for Hemophilia without Inhibitors
July 31, 2023
- UCB Submits Anti-Epileptic Drug Brivaracetam in Japan
July 31, 2023
- Nippon Shinyaku’s DMD Drug Nabs Breakthrough Therapy Designation
July 31, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…